Legalization of Cannabis Does Not Reduce Opioid Prescribing in Patients With Inflammatory Bowel Disease: A Difference-in-Difference Analysis

Author:

Noureldin Mohamed1,Van Tony2,Cohen-Mekelburg Shirley123ORCID,Scott Frank I.4ORCID,Higgins Peter D.R.1,Stidham Ryan W.135,Hou Jason67ORCID,Waljee Akbar K.12389ORCID,Berinstein Jeffrey A.13ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA;

2. VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, USA;

3. Institute of Healthcare Policy and Innovation, University of Medicine, Ann Arbor, MI, USA;

4. Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA;

5. Department of Computational Medicine and Bioinformatics University of Michigan Ann Arbor, Michigan;

6. Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA;

7. Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, TX, USA;

8. Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA;

9. Center for Global Health Equity, University of Michigan, Ann Arbor, MI, USA;

Abstract

INTRODUCTION: Cannabis may provide inflammatory bowel disease (IBD) patients with an alternative to opioids for pain. METHODS: We conducted a difference-in-difference analysis using MarketScan. Changes over time in rates of opioid prescribing were compared in states with legalized cannabis to those without. RESULTS: We identified 6,240 patients with IBD in states with legalized cannabis and 79,272 patients with IBD in states without legalized cannabis. The rate of opioid prescribing decreased over time in both groups and were not significantly different (attributed differential = 0.34, confidence interval −13.02 to 13.70, P = 0.96). DISCUSSION: Opioid prescribing decreased from 2009 to 2016 among patients with IBD in both states with legalized and state without legalized cannabis, similar to what has been observed nationally across a variety of diseases. Cannabis legalization was not associated with a lower rate of opioid prescribing for patients with IBD.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. A Study of Corporate Litigation Risks and Asset Openness under Green Eco-Development;Applied Mathematics and Nonlinear Sciences;2024-01-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3